SCHEMBL2198674

SCHEMBL2198674

O=C1NCCN1c1ccccn1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 1/20 0.63
ALOX5 P09917 1/20 0.58
PLD1 Q13393 1/20 0.53
CHEK1 O14757 1/20 0.46
AURKA O14965 1/20 0.46
DAPK3 O43293 1/20 0.46
JAK2 O60674 1/20 0.46
PRKD3 O94806 1/20 0.46
MAP4K4 O95819 1/20 0.46
PAK4 O96013 1/20 0.46
ABL1 P00519 1/20 0.46
NTRK1 P04629 1/20 0.46
FYN P06241 1/20 0.46
CSF1R P07333 1/20 0.46
RET P07949 1/20 0.46
IGF1R P08069 1/20 0.46
MET P08581 1/20 0.46
PDGFRB P09619 1/20 0.46
PIM1 P11309 1/20 0.46
FGFR1 P11362 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30702779 1.00 CRBN (0.63) CRBNALOX5PLD1CHEK1AURKA
SCHEMBL29090079 0.86 CRBN (0.55) CRBNALOX5PLD1CHEK1AURKA
SCHEMBL1161095 0.80 PLD1 (0.56) CRBNALOX5PLD1CHEK1AURKA
Hydrochloric Acid SCHEMBL1191652 0.78 PLD1 (0.54) CRBNALOX5PLD1CHEK1AURKA
SCHEMBL36363978 0.77 CRBN (1.00) CRBNALOX5PLD1CHEK1AURKA
SCHEMBL30910151 0.77 PIM1 (0.50) CRBNALOX5PLD1PIM1SMN1; SMN2
SCHEMBL22612095 0.77 CRBN (1.00) CRBNALOX5PLD1CHEK1AURKA
SCHEMBL26090875 0.77 PIM1 (0.50) CRBNALOX5PLD1PIM1SMN1; SMN2
SCHEMBL19913871 0.77 CRBN (0.54) CRBNALOX5PLD1CHEK1AURKA
SCHEMBL10847778 0.76 MAP3K5 (0.48) CRBNALOX5SMN1; SMN2ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4705284-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO Emory University (US) 2026-03-11 EP claimed
WO-2025235664-A1 PURINE NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO EMORY UNIVERSITY (US) 2025-11-13 WO claimed
WO-2024233354-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO EMORY UNIVERSITY (US) 2024-11-14 WO claimed
US-20060182762-A1 Enterovirus, vaccines, medicaments and diagnostic kits AMSTERDAM INSTITUTE OF VIRAL GENOMICS B.V. (NL) 2006-08-17 US claimed
EP-1625214-A1 NEW ENTEROVIRUS, VACCINES, MEDICAMENTS AND DIAGNOSTIC KITS Amsterdam Institute of Viral Genomics B.V. (NL) 2006-02-15 EP claimed
WO-2004104189-A1 NEW ENTEROVIRUS, VACCINES, MEDICAMENTS AND DIAGNOSTIC KITS AMSTERDAM INSTITUTE OF VIRAL GENOMICS B.V. (NL) 2004-12-02 WO claimed
US-20260124226-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO UNIV EMORY (US) 2026-05-07 US disclosed
EP-4705284-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO Emory University (US) 2026-03-11 EP disclosed
US-20250115581-A1 SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS MONTE ROSA THERAPEUTICS AG (CH) 2025-04-10 US disclosed
WO-2024233354-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO EMORY UNIVERSITY (US) 2024-11-14 WO disclosed
CN-116120282-B Compounds with EV71 and/or CVA16 virus inhibiting activity and application thereof 苏州系统医学研究所 2024-02-20 CN disclosed
WO-2023244817-A1 SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS MONTE ROSA THERAPEUTICS, INC. (US) 2023-12-21 WO disclosed
CN-116120282-A Compounds with EV71 and/or CVA16 virus inhibiting activity and application thereof 苏州系统医学研究所 2023-05-16 CN disclosed
EP-0200299-B1 PYRIDINYLIMIDAZOLIDINONE COMPOUNDS ELI LILLY AND COMPANY (US) 1990-10-10 EP disclosed
EP-0200299-A1 Pyridinylimidazolidinone compounds ELI LILLY AND COMPANY (US) 1986-11-05 EP disclosed
EP-0200299-A1 Pyridinylimidazolidinone compounds ELI LILLY AND COMPANY (US) 1986-11-05 EP disclosed
EP-0200299-A1 Pyridinylimidazolidinone compounds ELI LILLY AND COMPANY (US) 1986-11-05 EP disclosed
US-4600430-A HERBICIDES ELI LILLY AND COMPANY (US) 1986-07-15 US disclosed
US-4600430-A HERBICIDES ELI LILLY AND COMPANY (US) 1986-07-15 US disclosed
US-4600430-A HERBICIDES ELI LILLY AND COMPANY (US) 1986-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250115581-A1 SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS CKS1B, CSNK1A1, CKS2 CRBN 238/4885ALOX5 4773/4885PLD1 1066/4885
US-20060182762-A1 Enterovirus, vaccines, medicaments and diagnostic kits CD99, CD63, FAM83B CRBN 2190/4885ALOX5 4295/4885PLD1 4574/4885
US-20260124226-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO NSUN2, SARS1, SNRPE CRBN 1358/4885ALOX5 945/4885PLD1 2951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.